August 27, 2024 11:19 AM EDTUpdated 01:14 PM
News Briefing

Redalpine clos­es $200M fund; A base edit­ing pact in Chi­na; Mer­ck starts an­oth­er Phase 3 for Ima­go drug

ENDPOINTS

Plus, a Phase 3 fail from a small pub­lic com­pa­ny:

Redalpine’s $200M fund: The near­ly two-decade-old VC firm

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

HHS can re­quire ap­proval for drug­mak­ers to ap­ply 340B re­bate mod­els, court rules

A service from the Financial Times